Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
point decrease » point increase (Expand Search)
Showing 1 - 20 results of 273 for search '(( significant decrease decrease ) OR ( significant ((point decrease) OR (scores decreased)) ))~', query time: 0.66s Refine Results
  1. 1
    MiR-129-5p levels were decreased in mouse depression models.

    MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

    Published 2025
    “…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. The gray points represent miRNAs with no significant change (p < 0.05, false discovery rate (FDR) q < 0.05), while red and blue points indicate upregulated and downregulated miRNAs (p < 0.05, FDR q < 0.05), respectively. …”
    Save to List
    Saved in:
  2. 2
    Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx

    Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

    Published 2024
    Save to List
    Saved in:
  3. 3
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    The Fibrosis scoring by Sirius Red staining and SHG/TPEF.

    The Fibrosis scoring by Sirius Red staining and SHG/TPEF. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day).

    NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    The Laboratory Animal Flow Diagram.

    The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3).

    Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    General procedure for the synthesis of B.

    General procedure for the synthesis of B. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: